Clover Biopharmaceuticals (HKG: 2197), a leading biotechnology company based in China, has announced robust preliminary data from the Phase I clinical trial of its bivalent RSV candidate vaccine, SCB-1019. The vaccine, which targets both RSV-A and RSV-B, demonstrated significant increases in neutralizing titers, a key indicator of immune response. Specifically, the neutralizing titers for RSV-A and RSV-B were boosted to approximately 6,600 IU/mL (an increase of 6.4 times) and approximately 46,000 IU/mL (an increase of 12 times), respectively.
The data, presented at the American Association for Cancer Research (AACR) 2024 annual meeting, highlights the potential of SCB-1019 to provide comprehensive protection against RSV, a virus that poses a significant health risk to the elderly and young children. The vaccine candidate is based on Clover’s innovative protein trimer Tag vaccine technology platform, which has been designed to enhance the stability and immunogenicity of the vaccine.
Safety and tolerability profiles of SCB-1019 were also encouraging, with no dose-limiting toxicity observed across all dose groups. This is particularly important for a vaccine targeting RSV, where safety is a critical consideration given the vulnerable populations that the vaccine aims to protect.
Clover Bio is advancing SCB-1019 as a first-in-class vaccine candidate, and the positive preliminary results from the Phase I trial mark a significant step towards bringing a much-needed vaccine to market. The company is on track to release preliminary data from the target elderly population group in the second half of 2024, which could further substantiate the vaccine’s potential.- Flcube.com
